FindTrial
Sign In

Double Blind Study of TCV-116 in Patients with Hypertension

Double-blind comparative study of candesartan cilexetil/hydrochlorothiazide in patients with mild/moderate essential hypertension

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221017
Enrollment
Unknown
Registered
2010-02-23
Start date
2010-02-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Interventions

investigational material(s) Generic name etc : TCV-116C INN of investigational material : Candesartan cilexetil/hydrochlorothiazide Therapeutic category code : 214 Antihypertensives Dosage and Adminis

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Mild to moderate essential hypertension

Exclusion criteria

Exclusion criteria: 1.History or symptom of sever cardiovascular complication(hear failure,stroke) 2.Hypertension caused by other disease

Design outcomes

Primary

MeasureTime frame
Diastolic blood pressure—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026